Consistent with dietary n-3 LC-PUFA as adjunctive therapy, Volpato et al. (2016) found decreased plasma CCL2, a pro-inflammatory chemokine with known roles in metastasis, and longer disease-free survival in response to supplemental EPA, in CRC subjects undergoing surgery for liver metastasis [32]. The gene discussed is CCL2; the disease is colorectal carcinoma.